The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2:HER3 heterodimer.
Cecile Geuijen
Employment or Leadership Position - Merus
Eric Rovers
Employment or Leadership Position - Merus
Roy Nijhuis
Employment or Leadership Position - Merus
Renate den Blanken-Smit
Employment or Leadership Position - Merus
Therese Visser
Employment or Leadership Position - Merus
Willem Bartelink
Employment or Leadership Position - Merus
Arjen Kramer
Employment or Leadership Position - Merus
Vanessa Zondag-van der Zande
Employment or Leadership Position - Merus
Carina Clements
Employment or Leadership Position - Merus
Linda Kaldenberg
Employment or Leadership Position - Merus
Nellie Nieuwenhuizen
Employment or Leadership Position - Merus
Pieter Fokko van Loo
Employment or Leadership Position - Merus
Rob Roovers
Employment or Leadership Position - Merus
Tristan Gallenne
Employment or Leadership Position - Merus
Leo Price
Employment or Leadership Position - OcellO
Setareh Van Driel Shamsili
Employment or Leadership Position - Merus
Lex Bakker
Employment or Leadership Position - Merus
Ton Logtenberg
Employment or Leadership Position - Merus
Stock Ownership - Merus
John de Kruif
Employment or Leadership Position - Merus
Mark Throsby
Employment or Leadership Position - Merus